证券代码：万孚生物 证券简称：300482 编号： 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------|------------|-------------------------------------------------------------------------------------------------------------------------| | | | | | 投 资 者 关 系 活 动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | | 联讯证券、竣弘投资、东方资本、银石投资、融捷投资、银河证券、玖哥投 | | 人员姓名 | | 资、中航证券、亚宝投资、前海旗隆、冠丰资产、前海皇庭资本、长城证 券、厚生和投资、粤信金融、鹿峰投资。 | | 时间 | 2015-11-18 | | | ...

Group 1: Market Overview - The company has a high proportion of overseas market presence, with a focus on expanding quantitative products domestically [2] - New product registration in foreign markets takes longer, but sales increase significantly post-registration [2] - The largest market for similar products abroad is Europe, with a focus on OEM brands in large chain supermarkets [3] Group 2: Product and Sales Channels - The pregnancy testing market is primarily through supermarkets, with a growing emphasis on e-commerce platforms [3] - The company has a stable distribution network with no significant additional costs, mainly focusing on e-commerce expenses [3] - Infectious disease products are primarily self-branded, with some OEM for drugs and pregnancy tests [4] Group 3: Future Growth and Development - The company anticipates growth in drug testing markets outside of China and the U.S., with new testing varieties expected [4] - The market for chronic disease products is primarily quantitative, with significant sales potential in community healthcare settings [4] - The sales team has increased by approximately 10-20% domestically, with a larger demand in Europe and the U.S. [4] Group 4: New Product Development - The company plans to launch new platforms, including dry chemistry and microfluidics, in addition to existing qualitative and quantitative platforms [5] - Investments have been made in portable ECG devices as part of health management preparations [5]

Group 1: Company Overview - Guangzhou Wanfu Biological Technology Co., Ltd. offers qualitative and quantitative products, with pregnancy detection products being a notable example of qualitative products available in retail [2] - The company has been developing quantitative products for over five years, which provide specific numerical results and require machines for use [3] - The IVD market is growing annually, with Wanfu Biological maintaining a strong position and investing approximately 10% of sales revenue in R&D each year [3] Group 2: Market Performance - The quantitative products have seen over 30% annual growth in recent years, with higher gross margins compared to qualitative products [3] - Domestic sales accounted for approximately 60% of total sales in 2014, with a trend of increasing domestic sales and decreasing international sales [3] - The company expects domestic business to maintain around 20% annual growth, outpacing international market growth [4] Group 3: Competitive Landscape - Wanfu Biological differentiates itself from competitors like Meikang and Dirui by focusing on POCT (Point of Care Testing) and having a significant international sales presence [4] - The company’s main market includes secondary and tertiary hospitals, as well as community hospitals [4] Group 4: Product Development and Sales Strategy - The company plans to launch approximately 10 new products annually, focusing on extending existing product lines rather than diversifying into new areas [3] - Future quantitative products are expected to be launched in Europe and Asia, with heart attack-related products anticipated to be among the first [4] - The company is enhancing its international sales team to improve sales of quantitative products abroad, which require specialized knowledge for effective marketing and support [4][5] Group 5: Financial Outlook - The company’s performance is expected to remain stable, with no significant seasonal fluctuations in orders [5] - The depreciation of the RMB is beneficial for the company due to its substantial export share, which is projected to contribute positively to financial results [4]

证券代码：万孚生物 证券简称：300482 编号： 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------| | | | | | 投 资 者 关 系 活 动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | | 博时基金、中金蓝海资管、西南证券、民生银行、安信证券、尊道投资、尚 | | 人员姓名 | | 道投资、乐信资管、瑞天投资、通晟资产、广州证券、冠丰资产、广发资产 管理、中科沃土基金、华创证券、。 | | 时间 | 2016-5 ...

Group 1: Company Strategy and Market Position - The company focuses on three main areas: cardiovascular diseases, respiratory diseases, and infectious diseases, with the reproductive health sector being of lower strategic importance due to its limited market capacity [2]. - The company has been promoting its reproductive health products through e-commerce and various distributors, indicating future growth potential in this sector [2]. Group 2: Financial Performance and Growth - The company maintained a net profit growth rate of over 20% in the current year, despite a slowdown in growth over the past two years [3]. - The company invests over 10% of its revenue in research and development annually [3]. Group 3: Product Development and Innovation - The company has the only domestic product for sperm motility testing, which provides a competitive edge over other POCT industry companies [3]. - New products are expected to be launched annually, with a three-year planning cycle for product development [3]. Group 4: Sales and Marketing Strategy - The sales model is based on a distributor approach, with a goal of globalizing the business across R&D, production, and sales [4]. - Recent CE certifications for products related to myocardial infarction and heart failure are expected to enhance sales in Europe and the United States [4]. Group 5: Mergers and Acquisitions - The company aims to pursue technology-driven mergers and acquisitions to enhance its product line and production capabilities [4]. - The company has a stable history of operations and plans to maintain a cautious approach in investment activities [4]. Group 6: Government Support and Financial Impact - Government subsidies have remained stable at around 20 million, primarily supporting high-tech enterprises and biopharmaceutical research [4]. - As the company grows, the proportion of government subsidies to net profit is expected to decrease, indicating a reduced reliance on such support [4].

Product Overview - The company's main quantitative products include those related to myocardial infarction, heart failure, inflammation assessment, and glycosylated hemoglobin [2] - The growth rate of qualitative products is relatively stable, with no significant increase expected in the near term [2] - New instruments and related quantitative products will be launched in the future, with details available in periodic reports [3] Future Planning - The three-year plan for quantitative products includes expanding the product line, planning for international product platforms, maintaining stable growth in quantitative products, and launching new quantitative products while expanding into overseas markets [3] - The company has research and reserves for raw materials, primarily focusing on biological raw materials [3] - There are currently no plans for external mergers and acquisitions [3] Market Insights - Sales of drug testing products are relatively stable, with future growth expected mainly in regions outside of Europe and the United States [3] - The primary sales channels for reproductive health products are supermarkets, e-commerce, and OTC channels [3] Research and Development - A laboratory was established in San Diego, USA, in 2015, staffed mainly by American-Chinese personnel, focusing on the development of new products and improvement of existing products [4]

Group 1: Company Goals and Strategy - The company aims to achieve a revenue target of 10 billion in 10 years, based on strategic planning conducted by professional institutions [2] - To reach this target, the company needs to achieve an annual growth rate of 30%-40%, which requires expanding beyond current POCT products into IVD and medical device products [2] Group 2: Financial Performance and Market Impact - The gross margin for pregnancy test strips is lower due to increased sales proportion, while the overall gross margin is affected by declining prices of domestic pregnancy products [3] - The depreciation of the RMB positively impacts the company as export sales significantly exceed the increased costs of imported raw materials [3] Group 3: Market Coverage and Client Distribution - The company has approximately 15% market share in tertiary hospitals, with a focus on ICU and emergency departments [3] - Coverage in grassroots hospitals is around 20%, indicating a significant market presence [4] Group 4: Product Development and Innovation - The company plans to enhance product sensitivity through optimization of biological raw materials and microfluidic technology [4] - New products are expected to be launched in the US market, including low-sensitivity drug tests and tumor marker detection products [4] Group 5: Sales Strategy and Market Positioning - The company employs a deep marketing strategy for quantitative products, while qualitative products are sold through provincial agents [5] - The company is focused on maintaining gross margins by continuously launching new products and optimizing production costs [5] Group 6: International Market Challenges - The company faced challenges in the Americas and Africa markets in 2015, attributed to a lack of new product launches and insufficient marketing personnel [5] - Future marketing efforts will concentrate on the US market, with plans to enhance bidding qualifications for better market penetration [5]

证券代码：万孚生物 证券简称：300482 编号： 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 投 资 者 关 系 活 动 | □ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □ 新闻发布会□路演活动 | | | □现场参观 | | | □ 其他（请文字说明其他活动内容） | | 参 与 单 位 名 称 及 | 中信建设证券、长城医药、和骞投资、广证恒生等。 | | 人员姓名 | | | 时间 | 2017-5-12 | | 地点 | 公司 | | 上 市 公 司 接 待 人 员姓名 | 董秘：陈斌 | | 投 资 者 关 系 活 动 | 介绍： ...

证券代码：万孚生物 证券简称：300482 编号：2020-001 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------------|----------------------------|-------|--------------------------------------------------------------------------| | | | | | | 投 资 者 关 系 活 动 | □ 特定对象调研 □分析师会议 | | | | 类别 | □ 媒体采访 □业绩说明会 | | | | | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | | | √其他 电话会议，投资者线上交流会 | | 参 与 单 位 名 称 及 | | | 海通证券、易方达基金管理有限公司、景顺长城基金管理有限公司、中国人 | | 人员姓名 | | | 保资产管理有限公司、光大保德信基金管理有限公司、前海开源基金管理有 | | | | | 限 公 司 、 富 国 基 金 管 理 有 限 公 司 ...

证券代码：万孚生物 证券简称：300482 编号： 1 广州万孚生物技术股份有限公司投资者关系活动记录表 | --- | --- | |----------------------|---------------------------------------------------------------------| | | | | 投 资 者 关 系 活 动 | □ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □ 新闻发布会□路演活动 | | | □现场参观 | | | √ 其他 投资者交流会 | | 参 与 单 位 名 称 及 | 华泰瑞联、中信证券资管、广发基金、兴全基金、易方达基金、景顺长城基 | | 人员姓名 | 金、宝盈基金、安信证券、长江证券、国金证券、中信证券、华夏基金等 | | 时间 | 2019-09-10 | | 地点 | 公司及广州市天河区华观路 1961 号 | | 上 市 公 司 接 待 人 | 董事长王继华及公司核心经营管理团队。 | | 员姓名 | | | 投 资 者 关 系 活 动 | 1、Q: 行业未来是否会出现类似于现在心标、传染 ...